PILOT STUDY FOR IDENTIFYING URINARY PROSTATE CANCER BIOMARKERS

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 尿前列腺癌蛋白生物标记物对癌症的早期检测具有重要意义。此时的尿检可以显著减少因血清PSA升高而进行的不必要的活检次数。基因组学在癌细胞上的应用使人们能够确定一些候选生物标记物，以便进行进一步的研究。这项初步研究将利用先进的靶向蛋白质组技术，使用资源中心下的多反应监测(MRM)来测试尿样中已识别的癌症蛋白质的区分能力。预计该应用还将推动目标MRM技术的进一步开发和优化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Urinary prostate cancer protein biomarkers are important for early cancer detection. A urine test at this point can significantly reduce the number of unnecessary biopsies done as a result of elevated serum PSA. The application of genomics to cancer cells has allowed the identification of a number of candidate biomarkers for further investigations. This pilot study will utilize the advanced targeted proteomic technology using multiple reaction monitoring (MRM) under the resource center for testing the discriminatory power of identified cancer proteins in urine samples. The application is also anticipated to drive further development and optimization of the targeted MRM technology.